Wellington Biomedical Innovation Master Investors (Cayman) I L.P.

CIK 000178709216 companiesBOSTON, MA

SEC Profile

Transactions

Companies

Filings

CIK

0001787092

Recent Transactions

47 trades

Conversion
Zenas BioPharma, Inc.$ZBIO
Series C Convertible Preferred Stock
2024-09-16−1,742,858→ 0 total
Conversion
Zenas BioPharma, Inc.$ZBIO
Common Stock
2024-09-16+180,635→ 180,635 total
Conversion
Zenas BioPharma, Inc.$ZBIO
Common Stock
2024-09-16+200,718→ 801,624 total
Conversion
Zenas BioPharma, Inc.$ZBIO
Common Stock
2024-09-16+420,271→ 600,906 total
Conversion
Zenas BioPharma, Inc.$ZBIO
Series A Convertible Preferred Stock
2024-09-16−1,568,480→ 0 total
Conversion
Zenas BioPharma, Inc.$ZBIO
Series B Convertible Preferred Stock
2024-09-16−3,649,263→ 0 total
Conversion
Artiva Biotherapeutics, Inc.$ARTV
Common Stock
2024-07-22+145,089→ 145,089 total
Conversion
Artiva Biotherapeutics, Inc.$ARTV
Series B Preferred Stock
2024-07-22−145,089→ 0 total
Other
Artiva Biotherapeutics, Inc.$ARTV
Common Stock
2024-07-22$10.20/sh+49,019→ 194,108 total
Conversion
Boundless Bio, Inc.$BOLD
Common Stock
2024-04-02+366,300→ 556,233 total
Conversion
Boundless Bio, Inc.$BOLD
Series C Preferred Stock
2024-04-02−7,142,857→ 0 total
Conversion
Boundless Bio, Inc.$BOLD
Series B Preferred Stock
2024-04-02−3,703,704→ 0 total
Conversion
Boundless Bio, Inc.$BOLD
Common Stock
2024-04-02+189,933→ 189,933 total
Conversion
Acrivon Therapeutics, Inc.$ACRV
Common Stock
2022-11-17+888,130→ 888,130 total
Conversion
Acrivon Therapeutics, Inc.$ACRV
Series B Preferred Stock
2022-11-17−2,190,131→ 0 total
Conversion
Nuvalent, Inc.$NUVL
Series B Preferred Stock
2021-08-02−4,831,384→ 0 total
Conversion
Nuvalent, Inc.$NUVL
Class A Common Stock
2021-08-02+897,671→ 897,671 total
Conversion
Verve Therapeutics, Inc.
Series B Preferred Stock
2021-06-21−10,671,482→ 0 total
Conversion
Verve Therapeutics, Inc.
Series A-2 Preferred Stock
2021-06-21−12,436,264→ 0 total
Conversion
Verve Therapeutics, Inc.
Common Stock
2021-06-21+1,152,490→ 2,495,571 total
Conversion
Verve Therapeutics, Inc.
Common Stock
2021-06-21+1,343,081→ 1,343,081 total
Conversion
Edgewise Therapeutics, Inc.$EWTX
Common Stock
2021-03-30+681,812→ 681,812 total
Conversion
Edgewise Therapeutics, Inc.$EWTX
Series C Preferred Stock
2021-03-30−681,812→ 0 total
Conversion
Olema Pharmaceuticals, Inc.$OLMA
Common Stock
2020-11-23+451,986→ 1,725,406 total
Conversion
Olema Pharmaceuticals, Inc.$OLMA
Series C Preferred Stock
2020-11-23−451,986→ 0 total
Conversion
Olema Pharmaceuticals, Inc.$OLMA
Common Stock
2020-11-23+1,273,420→ 1,273,420 total
Conversion
Olema Pharmaceuticals, Inc.$OLMA
Series B Preferred Stock
2020-11-23−1,273,420→ 0 total
Conversion
Aligos Therapeutics, Inc.$ALGS
Common Stock
2020-10-20+571,143→ 1,906,191 total
Conversion
Aligos Therapeutics, Inc.$ALGS
Series B-2 convertible Preferred Stock
2020-10-20−571,143→ 0 total
Conversion
Aligos Therapeutics, Inc.$ALGS
Common Stock
2020-10-20+1,335,048→ 1,335,048 total
Conversion
Aligos Therapeutics, Inc.$ALGS
Series B-1 convertible Preferred Stock
2020-10-20−1,335,048→ 0 total
Conversion
PMV Pharmaceuticals, Inc.$PMVP
Series D Preferred Stock
2020-09-29−760,267→ 0 total
Conversion
PMV Pharmaceuticals, Inc.$PMVP
Common Stock
2020-09-29+760,267→ 760,267 total
Conversion
Dyne Therapeutics, Inc.$DYN
Series B Preferred Stock
2020-09-21−5,336,179→ 0 total
Conversion
Dyne Therapeutics, Inc.$DYN
Common Stock
2020-09-21+1,608,785→ 1,608,785 total
Conversion
Kymera Therapeutics, Inc.$KYMR
Series C Preferred Stock
2020-08-25−1,529,847→ 0 total
Conversion
Kymera Therapeutics, Inc.$KYMR
Common Stock
2020-08-25+959,211→ 959,211 total
Conversion
Nurix Therapeutics, Inc.$NRIX
Series D Preferred Stock
2020-07-28−784,313→ 0 total
Conversion
Nurix Therapeutics, Inc.$NRIX
Common Stock
2020-07-28+784,313→ 784,313 total
Conversion
Forma Therapeutics Holdings, Inc.
Common Stock
2020-06-23+1,252,913→ 1,252,913 total
Purchase
Forma Therapeutics Holdings, Inc.
Common Stock
2020-06-23$20.00/sh+1,000,000→ 2,252,913 total
Conversion
Forma Therapeutics Holdings, Inc.
Series D Convertible Preferred Stock
2020-06-23−5,359,344→ 0 total
Purchase
Generation Bio Co.$GBIO
Common Stock
2020-06-16$19.00/sh+1,100,000→ 2,112,546 total
Conversion
Generation Bio Co.$GBIO
Common Stock
2020-06-16+1,012,546→ 1,012,546 total
Conversion
Generation Bio Co.$GBIO
Series C Preferred Stock
2020-06-16−1,788,460→ 0 total
Conversion
Black Diamond Therapeutics, Inc.$BDTX
Series C Preferred Stock
2020-02-03−1,713,541→ 0 total
Conversion
Black Diamond Therapeutics, Inc.$BDTX
Common Stock
2020-02-03+568,185→ 568,185 total

Companies

Recent Filings

Address

C/O WELLINGTON MANAGEMENT COMPANY LLP 280 CONGRESS STREET

BOSTON, MA, 02210

View on SEC.gov